Grufity logoGrufity logo

RPRX

43.85USD-0.19(-0.43%)Market Closed

Royalty Pharma plc

Market Summary

USD43.85-0.19Market Closed
-0.43%

RPRX Alerts

RPRX Stock Price

RSI Chart

Valuation

Market Cap

18.7B

Price/Earnings

40.03

Price/Sales

8.26

Price/Cashflow

9.35

MarketCap/EBT

20.84

Price/Sales

Profitability

EBT Margin

39.62%

Return on Equity

4.48%

Return on Assets

2.63%

Fundamentals

Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

-2.1%

Revenue Q/Q

7%

Earnings

Earnings (TTM)

506.8M

Earnings Y/Y

39.95%

Earnings Q/Q

-53.15%

Price Action

52 Week Range

44.47
(Low)(High)

Last 7 days

2.0%

Last 30 days

4.2%

Last 90 days

4.7%

Trailing 12 Months

14.9%

Financial Health

Current Ratio

19.22

Debt/Equity

0.68

Debt/Cashflow

0.28

Investor Care

Dividend Yield

1.24%

Dividend/Share (TTM)

0.36

Shares Dilution (1Y)

6.59%

Diluted EPS (TTM)

1.14

Peers (Alternatives to Royalty Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.4T
394.3B
2.09% -9.22%
23.61
5.98
7.79% 5.41%
1.8T
203.1B
16.19% -21.88%
25.2
8.66
15.22% 2.81%
1.3T
282.1B
15.80% -29.87%
18.7
4.44
17.94% -5.14%
960.3B
502.2B
2.18% -45.23%
84.81
1.91
9.66% -56.89%
MID-CAP
2.5B
8.6B
2.72% -42.67%
-5.69
0.31
76.30% -20.89%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
1.6B
8.77% 21.76%
12.45
1.23
81.91% 208.48%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.4B
40.0M
-13.64% -71.15%
-1.84
34.64
34.91% -55.12%
1.0B
247.8M
11.54% -12.57%
-17.78
4.46
23.41% -194.70%
1.0B
412.4M
14.61% -28.22%
-153.63
2.47
51.09% -102.33%
988.1M
439.7M
-3.05% -78.77%
-2.97
2.13
-5.64% -199.38%
861.5M
1.2B
6.13% -46.00%
2.31
0.73
7.66% 583.60%
551.2M
2.2M
-7.04% -70.05%
-1.55
343.43
-72.60% -50.32%

Financials for Royalty Pharma

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.5%2,2472,2592,2782,2892,286
  S&GA Expenses1.1%200198191183187
  R&D Expenses-22.0%230295298200104
Earnings Before Taxes-0.2%8948951,2101,2411,554
Net Income8.7%5074666026201,398
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.4%17,67317,74017,37917,51617,732
  Current Assets-33.2%2,3423,5042,9822,8782,776
    Cash Equivalents-53.0%9922,1081,7921,5411,801
Liabilities-1.0%7,2567,3327,2377,2677,346
  Current Liabilities520.7%1,132182136171255
  Long Term Debt0.1%7,1117,1067,1017,0967,091
    LT Debt, CurrentInfinity%997----
    LT Debt, Non Current-14.0%6,1157,1067,1017,0967,091
Shareholder's Equity0.1%10,41610,40810,14210,24910,387
  Retained Earnings2.4%2,5052,4462,2252,2552,321
  Additional Paid-In Capital1.7%3,6333,5713,5433,5083,454
Shares Outstanding0.5%436434428--
Minority Interest-2.7%4,2644,3814,3644,4724,594
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations3.5%2,0641,9951,9522,0182,093
  Share Based Compensation-3.2%334
Cashflow From Investing-40.9%-1,995.81-1,416.16-1,259.81-1,870.28-2,151.04
Cashflow From Financing-326.7%-877.38387391385306
  Buy Backs-0
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on RPRX?

70.5%


Probability that Royalty Pharma stock will be more than 20% underwater in next one year

10.8%


Probability that Royalty Pharma stock will be more than 30% underwater in next one year.

0%


Probability that Royalty Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RPRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Royalty Pharma was unfortunately bought at previous high price.

Returns

Cumulative Returns on RPRX

Which funds bought or sold RPRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Aurora Investment Counsel
REDUCED
-48.35
-1,192,000
1,253,000
0.95%
2022-11-23
Toroso Investments, LLC
ADDED
3.89
-12,000
1,719,000
0.07%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
62.27
316,000
890,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-1,284,000
23,467,000
0.04%
2022-11-21
FourThought Financial, LLC
-
-
-1,000
-
-%
2022-11-18
Industrial Alliance Investment Management Inc.
REDUCED
-15.88
-898,000
3,682,000
0.11%
2022-11-17
M&T Bank Corp
-
-
-9,000
428,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
1,214,000
1,214,000
0.01%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
22,175.7
2,566,000
2,578,000
0.01%
2022-11-16
Neo Ivy Capital Management
NEW
-
255,000
255,000
0.67%

1–10 of 44

Latest Funds Activity

Are funds buying RPRX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own RPRX

Royalty Pharma News

Invest Chronicle

A Little Luck Can Go a Long Way with a Royalty Pharma plc (RPRX).45 hours ago

GuruFocus.com

RPRX Fair Value

Recent SEC filings of Royalty Pharma

View All Filings
Date Filed Form Type Document
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
APP ORDR
APP ORDR
Nov 21, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 08, 2022
8-K
Current Report
Nov 08, 2022
10-Q
Quarterly Report
Nov 04, 2022
4
Insider Trading
Nov 01, 2022
APP NTC
APP NTC
Oct 04, 2022
SC 13D/A
13D - Major Acquisition

Latest Insider Trading transactions for RPRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-22
Lloyd George W.
SOLD
-624,878
43.1874
-14,469
EVP, Investments & CLO
2022-11-22
Lloyd George W.
SOLD
-81,969
43.1416
-1,900
EVP, Investments & CLO
2022-11-21
Lloyd George W.
SOLD
-133,638
43.109
-3,100
EVP, Investments & CLO
2022-11-21
Lloyd George W.
SOLD
-885,081
43.1095
-20,531
EVP, Investments & CLO
2022-11-17
RIGGS RORY B
SOLD
-5,079,920
42.3327
-120,000
-
2022-11-10
Lloyd George W.
SOLD
-1,096,290
43.8515
-25,000
EVP, Investments & CLO
2022-11-10
Lloyd George W.
SOLD
-1,096,320
43.853
-25,000
EVP, Investments & CLO
2022-11-08
Coyne Terrance P.
SOLD
-1,065,010
43.4699
-24,500
EVP & CFO
2022-11-02
Coyne Terrance P.
SOLD
-236,846
43.0629
-5,500
EVP & CFO
2022-09-22
Giuliani Mario Germano
SOLD
-8,702,110
41.1681
-211,380
-

1–10 of 50

Pablo G. Legorreta
70
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues$ 573,463$ 585,773$ 1,671,467$ 1,713,763
Operating expenses    
Provision for changes in expected cash flows from financial royalty assets305,061137,837595,396186,337
Research and development funding expense25,50090,500126,60696,263
Amortization of intangible assets05,7965,67017,200
General and administrative expenses50,69248,588154,075136,665
Total operating expenses, net381,253282,721881,747436,465
Operating income192,210303,052789,7201,277,298
Other expense/(income)    
Equity in losses/(earnings) of equity method investees3,251(2,749)2,117(18,532)
Interest expense46,97744,327141,006119,168
(Gains)/losses on derivative financial instruments(25,785)16,972(97,590)21,436
(Gains)/losses on equity securities(5,168)19,28922,97017,980
(Gains)/losses on available for sale debt securities(44,243)14,885(97,985)(8,246)
Interest income(14,034)(12,261)(34,482)(42,896)
Other non-operating expense, net10,79879313,590858
Total other (income)/expenses, net(28,204)81,256(50,374)89,768
Consolidated net income before tax220,414221,796840,0941,187,530
Income tax expense0000
Consolidated net income220,414221,796840,0941,187,530
Net income attributable to non-controlling interests77,763119,867341,178575,706
Net income attributable to Royalty Pharma plc$ 142,651$ 101,929$ 498,916$ 611,824
Earnings per Class A ordinary share:    
Basic (in dollars per share)$ 0.32$ 0.24$ 1.14$ 1.49
Diluted (in dollars per share)$ 0.32$ 0.24$ 1.14$ 1.49
Weighted average Class A ordinary shares outstanding:    
Basic (in shares)439,293428,230436,542409,253
Diluted (in shares)607,226607,174607,209607,152
Financial Royalty Assets    
Revenues$ 551,682$ 505,832$ 1,578,555$ 1,538,871
Intangible Royalty Assets    
Revenues1,07363,40637,196139,594
Royalty Income, Other    
Revenues$ 20,708$ 16,535$ 55,716$ 35,298

RPRX Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 991,628$ 1,541,048
Marketable securities139,926581,872
Financial royalty assets675,857614,351
Accrued royalty receivable15,71253,286
Available for sale debt securities409,34766,000
Other royalty income receivable19,13115,023
Other current assets90,5156,631
Total current assets2,342,1162,878,211
Financial royalty assets, net14,287,39913,718,245
Intangible royalty assets, net05,670
Equity securities262,820269,800
Available for sale debt securities339,800204,400
Equity method investments409,857435,394
Other assets30,6134,145
Total assets17,672,60517,515,865
Current liabilities  
Distributions payable to non-controlling interests105,731107,934
Accounts payable and accrued expenses16,1125,620
Interest payable13,19957,696
Current portion of long-term debt996,5830
Total current liabilities1,131,625171,250
Long-term debt6,114,6777,096,070
Other liabilities9,9000
Total liabilities7,256,2027,267,320
Commitments and contingencies
Shareholders’ equity  
Deferred shares, $0.000001 par value; 369,265 and 361,170 issued and outstanding, respectively00
Additional paid-in capital3,632,9033,507,533
Retained earnings2,504,9742,255,179
Non-controlling interests4,264,3034,471,951
Accumulated other comprehensive income16,90416,491
Treasury interests(2,788)(2,715)
Total shareholders’ equity10,416,40310,248,545
Total liabilities and shareholders’ equity17,672,60517,515,865
Class A Ordinary Shares  
Shareholders’ equity  
Common stock4443
Class B Ordinary Shares  
Shareholders’ equity  
Common stock00
Class R Redeemable Shares  
Shareholders’ equity  
Common stock$ 63$ 63